Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,687.00+3.84%ETH$2,439.72+6.63%GOLD$4,072.20+3.34%OIL$88.04-8.38%
Smart Investors Daily
SID Premium
RV

NASDAQ · RVMDW

Revolution Medicines, Inc. Warrant

Healthcare · Biotechnology

$10.18

Up+$0.50 (+4.91%)

Updated Nov 4, 2026, 10:44 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
154.68M
P/E ratio
-15.46
Dividend yield
0.00%
52-week range
$1.53 – $13.44
Volume
8.95K
Avg. volume
28.36K

Price performance · RVMDW

RVMDW price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

RVMDW closed at $10.18 after 21 trading sessions, down 5.13% for the selected period.

Last close
$10.18
Period change
-5.13%
Period low
$8.40
Period high
$10.76
Daily close
View OHLC price history
RVMDW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$10.20$10.25$10.00$10.188.95K
Nov 2, 2026$9.99$9.99$9.4501$9.6010.34K
Oct 30, 2026$9.65$9.81$9.45$9.815.61K
Oct 29, 2026$9.58$9.855$9.58$9.63519.22K
Oct 28, 2026$9.20$9.55$9.20$9.552.82K
Oct 27, 2026$9.01$9.42$8.80$9.3256.78K
Oct 26, 2026$9.255$9.35$8.85$8.8518.53K
Oct 23, 2026$9.50$9.58$9.37$9.376.99K
Oct 22, 2026$9.71$10.15$9.09$9.330141.01K
Oct 21, 2026$10.74$11.08$10.19$10.3143K
Oct 20, 2026$9.90$10.405$9.90$10.4056.07K
Oct 19, 2026$8.29$8.86$8.29$8.798.74K
Oct 16, 2026$9.00$9.00$8.17$8.4069.53K
Oct 15, 2026$9.99$10.01$9.765$9.7654.18K
Oct 14, 2026$9.0301$10.35$9.0301$10.0035.44K
Oct 13, 2026$9.945$9.945$9.45$9.456.35K
Oct 12, 2026$9.41$10.11$9.25$10.088.01K
Oct 9, 2026$9.35$9.805$9.305$9.7654K
Oct 8, 2026$10.65$10.65$8.72$9.4475.64K
Oct 7, 2026$10.50$11.10$10.50$10.769.42K
Oct 6, 2026$11.30$11.30$10.30$10.7322.12K

Latest RVMDW news

The latest Smart Investors Daily articles mentioning RVMDW.

Stock researchCompany · Overview

RVMDW research

Overview

Company profile and research snapshot.

Company profile

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with chemotherapy across key subgroups, including patients with no identified tumor RAS mutation​Findings presented as late-breaking abstract during Proffered Paper session REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commerc

Yahoo · Oct 23, 2026

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib Vopimetostat combinations with RAS(ON) inhibitors daraxonrasib or zoldonrasib continued to be generally well-tolerated Registrational Phase 3 study of vopimetostat plus daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027 Investor webcast focused

Yahoo · Oct 21, 2026

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a

Yahoo · Oct 20, 2026

Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment

Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer. The trial tests the company’s investigational therapy, zoldonrasib, alongside standard care as a first-line treatment for adults with non-squamous non-small cell lung cancer harboring the RAS G12D mutation. Read Also: Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow Phase 3 Study Des

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By